The mechanisms by which some melanoma cells adapt to Serine/threonine-protein kinase B-Raf (BRAF) inhibitor therapy are incompletely understood. In the present study, we used mass spectrometry-based phosphoproteomics to determine how BRAF inhibition remodeled the signaling network of melanoma cell lines that were BRAF mutant and PTEN null. Short-term BRAF inhibition was associated with marked changes in fibronectin-based adhesion signaling that were PTEN dependent. These effects were recapitulated through BRAF siRNA knockdown and following treatment with chemotherapeutic drugs. Increased fibronectin expression was also observed in mouse xenograft models as well as specimens from melanoma patients undergoing BRAF inhibitor treatment. Analysis of a melanoma tissue microarray showed loss of PTEN expression to predict for a lower overall survival, with a trend for even lower survival being seen when loss of fibronectin was included in the analysis. Mechanistically, the induction of fibronectin limited the responses of these PTEN-null melanoma cell lines to vemurafenib, with enhanced cytotoxicity observed following the knockdown of either fibronectin or its receptor α 5 β 1 integrin. This in turn abrogated the cytotoxic response to BRAF inhibition via increased AKT signaling, which prevented the induction of cell death by maintaining the expression of the pro-survival protein Mcl-1. The protection conveyed by the induction of FN expression could be overcome through combined treatment with a BRAF and PI3K inhibitor.
INTRODUCTION
Serine/threonine-protein kinase B-Raf (BRAF) inhibitors are now the mainstay of systemic therapy for the 50% of patients whose melanomas harbor BRAF V600 mutations. [1] [2] [3] In the clinic, treatment with BRAF inhibitors such as dabrafenib and vemurafenib is associated with impressive responses, with significant levels of tumor shrinkage (as measured by Response Evaluation Criteria in Solid Tumors) being seen in the majority of patients. Most recently, a phase III randomized study (COMBI-D) has demonstrated an improved progression-free survival and overall response rate for patients treated with a combination of dabrafenib plus the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib versus dabrafenib alone, and a similar phase III trial has demonstrated improved overall survival (OS) in patients treated with the dabrafenib plus trametinib combination compared to vemurafenib monotherapy. 4, 5 Based on the durable objective responses observed to the combination of dabrafenib and trametinib, the combination gained FDA approval for treatment of unresectable BRAF V600E/K patients. Despite the initial success of BRAF inhibitor therapy, resistance is common in most patients, with the reactivation of the mitogenactivated protein kinase signaling pathway being observed in 470% of relapsing tumors. 2 Mechanistically, resistance to BRAF inhibition seems to follow a course of short-term adaptation in which small populations of cells evade therapy through increased phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/ AKT and mitogen-activated protein kinase signaling followed by the acquisition of mutations that sustain growth in the continual presence of drug. Emerging evidence suggests the initial adaptive responses to result in part from the relief of feedback inhibition at the level of Ras that sensitizes the melanoma cells to the pro-survival effects of exogenous growth factors (including IGF1R, PDGFR, c-MET, HER3 and FGFR). [6] [7] [8] [9] [10] It has been demonstrated that upregulation of expression and signaling through EGFR can also convey resistance to BRAF inhibition. 11, 12 Analysis of post-failure patient biopsies has identified multiple resistance mechanisms including mutations in NRAS, MEK1, MEK2 and BRAFsplice mutants. 7, 13, 14 Melanoma has the highest mutational load of all tumors, and frequently exhibits a complex genetic profile. Among these, melanomas that are both BRAF mutant and phosphatase and tensin homolog null (PTEN − ) sometimes show a reduced response to vemurafenib and dabrafenib. 15, 16 A recent analysis of melanoma patients stratified on the basis of their PTEN status, showed aberrant PTEN function not to be associated with the best overall response and these patients to show a trend toward a lower progression-free survival. 17 There is, however, evidence that some BRAF mutant/PTEN − melanoma cell lines still respond to BRAF or MEK inhibitor monotherapy suggesting that other co-operating factors may also contribute to intrinsic resistance. 18, 19 At this time, the mechanisms underlying the intrinsic resistance of some BRAF mutant/PTEN − melanomas to vemurafenib therapy remain poorly defined.
Most studies have focused on the genetic changes that are associated with acquired BRAF inhibitor resistance. In the current study, we used a proteomic approach to evaluate modulation of tyrosine phosphorylation in the short-term adaptive responses of BRAF V600E /PTEN − melanoma cell lines to BRAF inhibition. Through these methods, we uncovered a previously uncharacterized fibronectin (FN)-derived protective niche that is induced upon BRAF inhibition that drives therapeutic escape through α 5 β 1 integrin-mediated maintenance of pro-survival Mcl-1 expression.
RESULTS
Inhibition of BRAF is associated with adaptive changes in the signaling network To better understand the global vemurafenib-mediated adaptive changes in signaling, three BRAF V600E /PTEN − mutant melanoma cell lines were treated with either vehicle or vemurafenib (3 μM, 24 h), the tyrosine-phosphorylated peptides were captured by immunoprecipitation, and changes in the level of phosphorylation were analyzed by mass spectrometry ( Supplementary  Figure 1 ). 20, 21 Quantification of the tyrosine phosphorylation following BRAF inhibition using label-free MaxQuant (Max Planck Institute of Biochemistry, Martinsried, Germany) revealed changes in 73-83 distinct peptides, depending on the cell line (Figures 1a  and d; see Supplementary Table 1 for peptide list and phosphorylation sites identified). 22 Of these, alterations in 57 tyrosine-phosphorylated peptides were common to all three cell lines (Figures 1a and b ). GeneGO (Metacore, Thomson Reuters, New York, NY, USA) process network analysis of proteins exhibiting at a minimum of 10% change in phosphorylation highlighted changes in pathways implicated in cytoskeletal remodeling, receptor tyrosine kinase (RTK) signaling, integrinmediated adhesion and epithelial-to-mesenchymal transition (EMT; Figure 1c ). As expected, BRAF inhibitor treatment led to the inhibition of ERK1 and ERK2 phosphorylation in all of the cell lines tested (Figure 1d ). Mapping of these data using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (Kanehisa Laboratories, Kyoto University, Kyoto, Japan) revealed vemurafenib treatment to drive an adhesion signaling network involving integrin α 5 β 1 , Src, talin and FAK ( Figure 1e ). BRAF inhibitor-associated integrin/FN signaling A growth inhibition assay performed on a panel of PTEN − and PTEN + melanoma cell lines demonstrated that the vemurafenib IC50 was not correlated with PTEN expression, however, we have previously showed that PTEN expression in BRAF V600E cell lines does correlate with the extent of apoptosis induction following BRAF inhibition (Supplementary Figure 2 ). 15 A western blot analysis of a panel of melanoma cell lines showed the PTEN − cohort to express higher levels of integrin α 5 β 1 and basal pAKT than their PTEN + counterparts (Figure 2a ). As α 5 β 1 integrin signaling is activated through binding to FN, we next asked whether the adhesion phenotype identified using phosphoproteomics was the result of extracellular matrix (ECM) remodeling. BRAF V600E /PTEN − melanoma cell lines showed increased FN expression following vemurafenib treatment, an effect not observed in the BRAF V600E /PTEN + cohort (Figure 2b ; Supplementary Figure 3 ). Enzyme-linked immunosorbent assays showed an increase in active secretion of FN into the cell culture media (Figure 2c ). BRAF inhibition increased FN expression at the mRNA level as measured by RT-qPCR ( Figure 2d ). These effects were not restricted to vemurafenib treatment and were recapitulated following siRNA knockdown of BRAF (Figure 2e ; Supplementary Figures 6 and 7) as well as following treatment with cytotoxic drugs such as cisplatin, carboplatin and paclitaxel (Figure 2f ; Supplementary Figures 8 and 9 ). Vemurafenibmediated FN upregulation was evident as early as after 2 h of treatment (Supplementary Figure 10A ). The combination of the MEK inhibitor trametinib with vemurafenib showed a similar effect to vemurafenib monotherapy (Supplementary Figure 10B ). The upregulation of FN expression was coupled with extracellular deposition of FN as a functional matrix, as demonstrated by the ability of vemurafenib-induced FN to promote melanoma cell adhesion (Supplementary Figure 11 ). No changes in other ECM proteins that are known interactors of α 5 β 1 integrin (such as vitronectin) were noted (Supplementary Figure 12 ). Quantitative RT-PCR analysis of tumors from four patients failing vemurafenib therapy identified increased intratumoral FN in two cases ( Figure 2g ). Immunohistochemical (IHC) analysis of an additional group of patient specimens (n = 3) identified one tumor with higher FN expression in the post-BRAF inhibitor relapse sample that was absent in the initial specimen ( Figure 2h ). Integrin/FN signaling is crucial for melanoma cell survival on therapy Previous work from our group has shown that melanoma cell lines lacking PTEN expression can show reduced cytotoxicity following BRAF inhibitor treatment. 15 We next investigated whether increased FN expression secondary to BRAF inhibition could contribute to therapeutic escape. Knockdown of FN using an siRNA pool, as well as by three individual siRNAs, significantly increased vemurafenib-mediated apoptosis ( Figure 14A ). In these studies, cells were grown in 1% fetal bovine serum (FBS) to reduce the survival benefit from FN in the serum. The low serum levels increased basal levels of cell death particularly following treatment with the non-targeting siRNA. The protective effects were mediated through integrin α 5 β 1 , with siRNA knockdown of α 5 integrin found to significantly increase the level of vemurafenib-induced apoptosis (Figure 4c and Supplementary Figure 14B ). Mouse xenograft studies show an induction of FN expression in BRAF/PTEN − melanoma xenografts in response to treatment with the vemurafenib analog, PLX4720 ( Figure 4d ). In line with the reduced cytotoxicity seen in vitro due to FN upregulation, the BRAF inhibitor PLX4720 also exhibited significantly weaker antitumor activity in BRAF/PTEN − melanoma xenografts compared to BRAF/PTEN + xenografts (Figure 4e ). Unlike the tissue culture experiments, the BRAF V600E /PTEN − tumor xenografts were found to have basal FN expression ( Figure 4d ). We reasoned that this may have resulted from the increased stress the cells experience under xenograft conditions, and demonstrated that mild acidosis (pH 6.7)-such as that seen in vivo-was sufficient to induce FN expression in BRAF V600E /PTEN − cell lines (Supplementary Figures  14C and D) . The clinical significance of PTEN loss and increased FN expression was investigated on an annotated tissue microarray (TMA) of 93 individual stage III/IV melanoma patient specimens (Supplementary Tables 2-4 ). Here, PTEN loss was associated with significantly reduced (P o 0.05) OS (Figure 4f and Supplementary  Table 3 Treatment-associated integrin/FN signaling protects melanoma cells from vemurafenib-mediated cytotoxicity through increased PI3K/AKT signaling Previous work from our group and others has demonstrated BRAF/MEK inhibition to be associated with adaptive PI3K/AKT signaling. 15, 19 We next used kinome arrays and western blot studies to show that siRNA knockdown of FN abrogated the vemurafenib-mediated increases in AKT phosphorylation ( Figures  5a and b ). The protective role of PI3K/AKT signaling was confirmed by the ability of the PI3K inhibitor, GDC-0941, to enhance vemurafenib-mediated apoptosis and reduce survival in longterm colony formation assays (Figures 5c and d ). The enhanced Fibronectin promotes BRAF inhibitor resistance pro-apoptotic effects of combined BRAF/PI3K inhibition were PTEN dependent and were not observed in WM164 cells that are BRAF V600E /PTEN + (Figure 5e ). Liquid chromatography-multiple reaction monitoring mass spectrometry was next used to identify the BH3 family proteins required for FN-mediated survival (Figure 5f ; Supplementary Figure  15A ). 15, 23 These studies showed Mcl-1 expression to be dependent on signaling through α 5 integrin and FN, with siRNA knockdown of either of these proteins decreasing Mcl-1 expression when BRAF was inhibited (Figures 5f and h; Supplementary Figure 15A ). In line with FN being a stress-induced response in PTEN − cells, the expression of FN was upregulated in serum-starvation transfection conditions and in the presence of lipofectamine (Figure 5h ; Supplementary Figure 15B ). The adhesion-mediated Mcl-1 expression was also dependent on PI3K/AKT signaling with expression being reduced following treatment with the combination of vemurafenib and GDC0941 (Figure 5i ).
DISCUSSION
Melanoma cells readily adapt to nearly every treatment intervention and possess multiple routes to therapeutic escape. Understanding of the process of adaptation and resistance has been complicated by the diversity of signaling in melanoma and the ability of subtle alterations in levels of signaling molecules and RTKs to reduce sensitivity to BRAF and MEK inhibitors (for example, cyclin D1, COT, BRAF, CRAF, MEK1 mutations, PDGFR and IGF1R; reviewed in Fedorenko et al. 24 and Solit and Rosen 25 ).
In the current study, we used mass spectrometry-based phosphoproteomic analysis to identify a novel mechanism by which BRAF inhibition remodels the extracellular environment of melanoma cells and stimulating signaling through integrins, allowing for therapeutic escape.
Proteomic analysis of phosphotyrosine signaling, in a panel of BRAF V600E /PTEN − melanoma cell lines, demonstrated vemurafenib to induce signaling through proteins implicated in EMT, including α 5 β 1 integrin, FN, focal adhesion kinase (FAK), Src, paxillin and talin. 26 Previous mass spectrometry work, in which one BRAF mutant melanoma cell line was treated with the MEK inhibitor U0126, has already demonstrated a role for oncogenic BRAF in cytoskeletal regulation. 27 EMT has been best characterized in the oncogenic transformation of epithelial cells, where it is typified by increased motility, upregulated expression of ECM (such as FN), apoptosis resistance and drug resistance. 26, 28 Although melanocytes are neural crest derived and not epithelial in origin, the Fibronectin promotes BRAF inhibitor resistance introduction of mutant BRAF can lead to an EMT-like state. [29] [30] [31] We here provide evidence that inhibition of BRAF also induces an EMT-like phenotype in melanoma cells that lack PTEN expression. Loss of PTEN/increased AKT signaling mediates a mesenchymal switch in multiple epithelial tumor types including prostate cancer and nasopharyngeal tumors. [32] [33] [34] In BRAF V600E /PTEN − melanoma cells, the vemurafenib-induced EMT was characterized by increased FN/α 5 β 1 integrin signaling. These observations were not restricted to vemurafenib and could be recapitulated through cytotoxic chemotherapeutic drugs. Other cancer-relevant forms of stress, such as mild acidosis (pH 6.7) also increased FN expression in this system. These findings mirror those seen in breast cancer patients, where resistance to multiple drugs, including chemotherapeutic agents (paclitaxel and cisplatin), signal transduction inhibitors (PI3K, MEK and PI3K/mTOR inhibitors) and RTK inhibitors (EGFR, HER3 inhibitors) was associated with a switch to a more mesenchymal phenotype. 28 A link between loss of PTEN and increased FN deposition has been observed in other systems and is characteristic of pathological fibrotic states such as pulmonary fibrosis, where PTEN downregulation in infiltrating fibroblasts leads to increased FN deposition. 35, 36 Evaluation of a melanoma TMA demonstrated the role of PTEN loss as a negative prognostic factor with a significant correlation observed between decreased PTEN expression and worse OS. When FN expression was included in the survival analysis, patients whose tumors lacked PTEN and expressed high FN showed a poorer survival than those with tumors that retained PTEN and lacked FN expression (15.1 versus 45.2 months, median OS).
Attachment to extracellular matrix has been identified as an important mechanism of drug resistance in a number of tumor systems. In myeloma, β1-integrin-mediated adhesion serves to increase STAT3 signaling leading to increased Bcl-xL and decreased Bcl-2 interacting mediator of cell death (Bim) expression. 37 Protection from cytotoxic drugs has also been observed when lung cancer and ovarian cancer cells are adhered onto laminin and collagen. 38, 39 In a three-dimensional cell culture model of ovarian cancer, adhesion to reconstituted basement membrane mediated resistance to PI3K/mTOR inhibition. 40 Use of a reverse-phase protein array system revealed this matrix-driven protection to be mediated through increased EGFR, IGFR1 and c-KIT activity, leading to the suppression of apoptosis. The increase in cell survival was dependent on enhanced Bcl-2 protein expression and could be overcome through the combination of a PI3K/mTOR inhibitor and a Bcl-2 protein inhibitor or a PI3K/ mTOR inhibitor combined with an EGFR or IGF1R inhibitor. 40 In tissue culture studies, the induction of integrin/FN signaling limited the cytotoxic effects of vemurafenib. Mechanistically, integrin α 5 signaling was required for the maintenance of Mcl-1 expression, a key anti-apoptotic protein that exerts its effects through binding to BIM-EL and inhibition of pro-apoptotic Bak/Bax. 41, 42 In melanoma cells, adhesion to FN prevents the induction of anoikis through increased PI3K signaling. 43 The expression of Mcl-1 is regulated at the transcriptional level by PI3K/AKT and post-translationally by MEK-mediated phosphorylation events that prevents its proteasomal degradation. 41, 44 A role for the PI3K/AKT pathway in the integrin-mediated maintenance of Mcl-1 levels was suggested by the decreased AKT signaling seen following the siRNA knockdown of FN and the ability of the BRAF/PI3K inhibitor combination to downregulate Mcl-1 expression. The role of PI3K/AKT signaling in the adaptive responses that drive therapeutic escape was suggested by the finding that the BRAF/PI3K inhibitor combination led to increased cytotoxicity.
The observation that anti-cancer therapies induce the establishment of a pro-survival niche that allows for therapeutic escape is not without precedent. There is evidence from mouse xenograft studies that although radiation treatment induces massive cell death in tumors, it also generates signals that promote the survival of small numbers of tumor cells that can ultimately repopulate the tumor. In this instance, radiation-mediated apoptotic cell death led to caspase-3-dependent expression of prostaglandin E2, which limited cytotoxicity. 45 The importance of caspase-3 in this process was demonstrated by studies showing that animals deficient in this enzyme showed enhanced responses to radiation therapy. Supporting studies in human cancer patients further demonstrated that high levels of intratumoral caspase-3 predicted for an increased rate of cancer recurrence. 45 The ability of the tumor cells to adapt to therapy and provide a sanctuary for some of its own cells is likely to be of major clinical significance given that even one melanoma cell can establish new tumors in vivo. 46 Together, our data demonstrate a role for the PI3K/AKT signaling pathway as the major mediator of adhesionmediated protection. A number of clinical trials are now ongoing to determine whether the dual targeting of BRAF and PI3K/AKT can abrogate or delay the onset of resistance in BRAFmutant melanoma patients (NCT01902173, NCT01820364 and NCT01616199).
MATERIALS AND METHODS

Cell culture and reagents
The 1205Lu, WM9, WM793, WM164, WM983A and 451Lu melanoma cell lines were a generous gift from Dr Meenhard Herlyn (The Wistar Institute, Philadelphia, PA, USA) and were genotyped as being BRAF V600E mutant. WM793TR (tet repressor) cell line, engineered to inducibly express PTEN, was a generous gift from Dr Andrew Aplin (Kimmel Cancer Center, Philadelphia, PA, USA). Inducible expression of PTEN was achieved by treatment of cultures with 100 ng/ml doxycycline. The identities of all cell lines were confirmed by Biosynthesis Inc. (Lewisville, TX, USA) through short tandem repeat validation analysis. Cell lines were maintained in 5% FBS/RPMI-1640, and routinely tested for negative mycoplasma contamination. Acidic media experiments were carried out using DMEM/F12 containing 25 mM pipes, 25 mM HEPES and 10% FBS, then pH was adjusted using NaOH.
Phosphoproteomic sample preparation, liquid chromatographytandem mass spectrometry and analysis
Briefly, cells were lysed in denaturing buffer followed by protein reduction, alkylation and trypsin digestion. The tryptic peptides were then desalted. Following lyophilization, phosphotyrosine-containing peptides were enriched by immunoprecipitation with immobilized anti-phosphotyrosine antibody p-Tyr-100 (Cell Signaling Technology, Beverly, MA, USA). 20, 21 A nanoflow ultra high-performance liquid chromatograph (rapid separation liquid chromatography, Dionex, Sunnyvale, CA, USA) coupled to an electrospray ion trap mass spectrometer (LTQ Orbitrap, Thermo Fisher Scientific, San Jose, CA, USA) was used for tandem mass spectrometry peptide sequencing experiments. Sequest (Thermo Fisher Scientific) and Mascot (www.matrixscience.com) 47 searches were performed and the results were summarized in Scaffold 3.0 (www.proteomesoftware.com). The integrated peak areas for pY peptide quantification were calculated from extracted ion chromatograms using QuanBrowser from Xcalibur 2.0 (Thermo Fisher Scientific). Label-Free quantification was performed using MaxQuant (v. 1.2.2.5). 22 Heat maps of pY ion signals were generated using MultiExperiment Viewer (version 4.8.1, http://www.tm4.org). 48 Process network enrichment analysis was performed using GeneGO pathway maps in Metacore (Thomson Reuters, New York, NY, USA). Additional pathway analysis was performed using KEGG pathway database. 49 Both GeneGo and KEGG analyses were performed on proteins with a change in phosphorylation levels 410%.
Growth inhibition assay
Cells were plated in a 96-well plate and left to attach overnight before being treated with vehicle or increasing doses of vemurafenib for 72 h. Cells were then incubated with tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reagent (Sigma-Aldrich, St Louis, MO, USA) for 3 h, then crystals were solubilized in dimethyl sulfoxide followed by a measurement of absorbance at 570 nm.
Western blotting
Proteins were extracted using RIPA lysis buffer (0.5 M Tris, Triton X-100, Na-deoxycholate, 10% SDS, NaCl and 0.5M EDTA) containing cOmplete Mini protease inhibitor cocktail tablet (Roche, Indianapolis, IN, USA). Total protein was quantified using Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Protein extracts were resolved on Novex 8-16% Tris-glycine gels (Life Technologies, Carlsbad, CA, USA) and were electrophoretically transferred onto polyvinyl difluoride membranes (Millipore, Bedford, MA, USA). Membranes were blocked using 5% nonfat dry milk/TBST (Tris-buffered saline with tween 20) and incubated with primary antibody overnight at 4°C. Membranes were then incubation with isotype-specific horseradish peroxidase (HRP)-conjugated secondary antibody (Amersham Pharmacia, Little Chalfont, UK) diluted in 5% milk/TBST. Immunocomplexes were visualized using the enhanced chemiluminescence substrate (PerkinElmer, Waltham, MA, USA) and detected on an autoradiography film (Denville Scientific, Metuchen, NJ, USA). Uniform protein loading was confirmed by blotting for GAPDH. The antibodies to PTEN (9188), integrin α5 (4705), integrin β1 (4706), BRAF (9433), phospho-AKT S473 (4058), total AKT (9272), caspase 7 (9492), phospho-ERK (9101), total ERK (9102) and Mcl-1 (4572) were from Cell Signaling Technology. Laminin 5 (ab14509) antibody was purchased from Abcam (Cambridge, MA, USA), while the antibody against vitronectin (sc-28929) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). FN (610077) antibody was purchased from BD Biosciences (San Jose, CA, USA), GAPDH (G8795) was from Sigma-Aldrich and phalloidin (A22287) was from Invitrogen (Life Technologies).
Immunofluorescent staining
Melanoma cells were plated on glass coverslips in six-well plates and incubated overnight prior to treatment. Cells were then fixed using 4% paraformaldehyde solution (Electron Microscopy Sciences, Hatfield, PA, USA) and permeabilized with 0.2% Triton X-100 prior to being blocked in 1% bovine serum albumin (BSA)/phosphate-buffered saline (PBS). Coverslips were incubated with primary antibodies overnight at 4°C. Coverslips were then washed in PBS, incubated with secondary antibodies for 1 h at room temperature, and washed again in PBS and sterile water. Coverslips were mounted with ProLong Gold antifade reagent with 4',6-diamidino-2phenylindole (Life Technologies) and imaged using confocal microscopy.
RNA interference
Cells were plated and left to grow overnight in 5% FBS/RPMI. The following day, 5% FBS/RPMI media was replaced with Opti-MEM (Invitrogen). FN pool, FN siRNA A 5′-GACUGGUGGUUACAUGUUAtt-3′, FN siRNA B 5′-CG CAUCACUUGCACUUCUAtt-3′, FN siRNA C 5′-GAUCCUGUCUACUUCAC AAtt-3′, integrin α5 siRNA A 5′-GUCAGAAUUUCGAGACAAAtt-3′, integrin α5 siRNA B 5′-CCACUGACCAGAACUAGAAtt-3′, integrin β1 siRNA A 5′-GA GAUGAGGUUCAAUUUGAtt-3′, integrin β1 siRNA B 5′-GAUGAGGUUCAAUU UGAAAtt-3′ (25 nM, Santa Cruz Biotechnology), integrin α5, integrin β1 and PTEN (all 25 nM, Cell Signaling Technologies), and BRAF (25 nM, Thermo Scientific) siRNAs in complex with Lipofectamine 2000 (Invitrogen) were added. Scrambled, non-targeting siRNAs were used as controls.
A final concentration of 5% FBS in RPMI was added the next day. For FN knockdowns, final concentration of 1% FBS in RPMI was added next day. Cells were transfected for 24-72 h prior to treatment.
Kinase arrays
Phosphorylation levels of 43 phosphorylation sites on human kinases were determined using the Proteome Profiler human phospho-kinase array kit (R&D Systems, Minneapolis, MN, USA) following manufacturer's instructions.
Animal studies
Seven-week-old female BALB SCID mice (The Jackson Laboratory, Bar Harbor, ME, USA) were subcutaneously injected with 2.5 × 10 6 cells per mouse. Tumors were allowed to grow to until palpable. Mice were randomly separated into treatment cohorts of approximately equal average initial tumor volumes, three mice per treatment group. Mice were administered D10001 control chow or AIN-76A 417 mg/kg PLX4720formulated chow (Research Diets, New Brunswick, NJ, USA) daily. Mouse weights and tumor volumes (½ × L(length) × W(width) 2 ) were measured every 48 h. All animal experiments were carried out in compliance with ethical regulations and protocols approved by the University of South Florida Institutional Animal Care and Use Committee.
Enzyme-linked immunosorbent assays FN enzyme-linked immunosorbent assay kit was obtained from Millipore (Billerica, MA, USA), and used abiding by manufacturer's instructions.
qRT-PCR
Cells were treated for 72 h then total RNA was isolated using Qiagen's RNeasy mini kit (Valencia, CA, USA). The following TaqMan (Life Technologies) gene expression assay primer/probes were used: Hs00365052_m1 (FN), P/N 4319413E (18 S) and Hs99999905_m1 (GAPDH). The 18 S+GAPDH data were used to normalize FN. qRT-PCR reactions were performed in duplicate as previously described. 15 Analyzed cDNA from patient specimens was collected under approved protocols by the Institutional Review Board at Massachusetts General Hospital.
Flow cytometry
Cells were grown in six-well tissue culture plates overnight, then treated with vehicle (dimethyl sulfoxide ) 3 μM vemurafenib, 3 μM GDC-0941 or the two drugs in combination for 72 h. In some studies, cells were transfected with non-targeting siRNA or siRNAs targeting FN, integrin α 5 or integrin β1 for 24 h prior to treatment and harvested after 48 or 72 h of treatment. Cells were then washed with 1x annexin V binding buffer (BD Biosciences), resuspended in 100 μl of binding buffer containing 2 μl allophycocyaninconjugated annexin V (550474, R&D Systems) and 25 nmol/l tetramethylrhodamine, methyl ester and perchlorate (TMRM; Molecular Probes, Eugene, OR, USA). Cells were incubated at 37°C for 15 min before being analyzed for annexin V fluorescence and TMRM retention using flow cytometry. Gates were delineated based on regions of distinct populations.
Liquid chromatography-multiple reaction monitoring mass spectrometry
Liquid chromatography-multiple reaction monitoring mass spectrometry was performed as described previously. 23, 50 Protein expression was determined using the ratio of peak area of the endogenous peptide to corresponding internal standard; normalization of results was performed using GAPDH to accommodate differences in total protein loading. Data were then normalized to the non-targeting siRNA controls and graphed to show the changes in expression after transfection and drug treatment.
Colony formation
Cells were seeded out into six-well plates at 1 × 10 4 per well and grown overnight before being treated with vehicle, 3 μM vemurafenib, 3 μM GDC-0941 or the two drugs in combination. Cells were left to grow for 2 weeks with the new drug added twice per week. Wells were washed with PBS and stained with crystal violet solution (50% methanol+50% H 2 O +0.5% crystal violet).
TMA and patient specimens IHC staining of melanoma specimens and a TMA containing a spectrum of melanoma specimens was constructed and analyzed under approved protocols by the Institutional Review Board at the University of South Florida (including informed consent). It contained samples from four groups: primary cutaneous melanoma, lymph node metastases, dermal/subcutaneous metastases and visceral metastases. After identification of tumor tissue, two 1.5-mm cores were obtained from each donor block. For the TMA, a single core from each block was positioned on a grid of 100 samples processed with the Beecher Microarray System (Beecher Instruments, Sun Prairie, WI, USA). Targeted gene sequencing was performed on extracted DNA from the second core, and analyzed via the Sequenom platform (MassARRAY Analyzer 4, Sequenom, San Diego, CA, USA and MelaCarta Panel, Agena Bioscience, San Diego, CA, USA). Clinical data were collected from the patients. Medical records and the social security death index were searched for demographic, pathology, staging and recurrence/survival data. Analyses were performed using SPSS (IBM, Armonk, NY, USA) and SAS (SAS Institute Inc., Cary, NC, USA) softwares. TMA sections were evaluated for total FN and PTEN expression via IHC with optimized anti-FN (ab2413, Abcam) and anti-PTEN (E4250, Spring Bioscience, Pleasanton, CA, USA) antibodies in the Tissue Core at Moffitt Cancer Center. TMA was stained using a Ventana Discovery XT automated system (Ventana Medical Systems, Tucson, AZ, USA) following manufacturer's protocol with proprietary reagents. Detection was carried out using the Ventana ChromoMap Red kit (Ventana Medical Systems) with hematoxylin counterstain. Staining intensity was scored by the dermatopathologist as follows: absent staining = 0, weak staining = 1, moderate staining = 2 and strong staining = 3. For both markers, all tumor cells in the infiltrate showed diffuse, uniform staining. Dichotomous high and low FN levels were assigned based on IHC scores of 0-1 and 2-3, respectively. PTEN dichotomous scoring was assigned as absent (IHC = 0) versus present (IHC = 1-3).
Cell adhesion assay
1205Lu melanoma cells were plated onto six-well plates and allowed to attach overnight. They were then treated for 72 h with 3 μM vemurafenib. Following the treatment, the cells were detached using 10 mM EDTA in PBS. The plates were incubated overnight with 5% acetic acid at 4°C. Plates were then washed three times with PBS. These vemurafenib-induced FN plates were compared to regular plastic cell culture plates, and commercially available FN-coated plates from BD Biosciences. 1205Lu cells were plated onto these plates and monitored for cell attachment after a 15-min incubation period. The cells were fixed with 4% paraformaldehyde and stained with crystal violet. Cells were imaged, and nine frames from each surface was used for cell counts.
Densitometry
The mean pixel intensity for each band and the background was determined. The background was subtracted from each sample and the resulting value was divided by the appropriate control.
Statistical analysis
Results are reported as mean values, error bars indicating ± s.e.m., calculated from three biological replicates unless otherwise indicated. Sample sizes are calculated to allow significance to be reached. Prism 6 software (GraphPad Software, La Jolla, CA, USA) was used to calculate statistical significance of magnitude of changes between different conditions was calculated using the parametric unpaired t-test with P-values depicted as follows: *P ⩽ 0.05, **P ⩽ 0.01, ***P ⩽ 0.001 and ****P ⩽ 0.0001.
